Johnson Johnson Walking Away Could Boost Long-Term Value
Johnson Johnson walking away from a GLP-1 obesity obsession signals a shift to a diversified, potentially more resili...
Eli Lilly
Discover Eli Lilly stock insights from 4 articles covering long-term bets, timing questions, bullishness priced in, and FDA news. Learn what matters and refine portfolio today.
39 articlesLilly Price Prediction: Case for Double-Digit Upside
Eli Lilly faces a pivotal year as its GLP-1 franchise powers revenue growth and new oral therapies expand addressable...
Reasons Lilly Better Stock: 5 Clear Advantages Over SpaceX
Investors face a choice between a pharmaceutical powerhouse with proven earnings and a high-growth space company unde...
Is Lilly Stock Undervalued Healthcare Play Right Now?
Is Lilly stock undervalued healthcare? This article breaks down the valuation case, growth catalysts, risks, and a pr...
Analyst Just Declared Lilly the Clear Winner at ADA Conference
The ADA conference spotlighted Lilly and Novo Nordisk in the GLP-1 race. This deep dive explains what the claims mean...
Lilly vs Pfizer: Obesity Race Reaches Market Highs
Lilly leads the GLP-1 obesity wave as Pfizer rebuilds with deals and repurposed assets. Q1 2026 results underscore tw...
Reasons Lilly Stock: 5 Key Upsides Investors Should Watch
This deep dive looks at why Lilly stock may be a standout pick for growth-focused investors. From a dominant obesity ...
Prediction: Lilly Will Trade at $1,200 by Year-End
Investors weigh a bold forecast that Eli Lilly could hit $1,200 by year-end 2026, betting on GLP-1 drugs and a robust...
Should Lilly Stock Wait: Timing Eli Lilly Stock for a Dip
Eli Lilly stands at a pivotal moment for investors. With a massive market-cap and a growing GLP-1 portfolio, the ques...
Reasons Lilly Stock Like There’s No Tomorrow: A Bold Buy
Seeking a stock with growth, resilience, and optionality? This article lays out three strong reasons to consider Lill...
Abridge Wants Operating System for Medicine Backed by NVIDIA
Abridge secures NVIDIA and Eli Lilly support to push an ambient AI platform toward a full hospital operating system. ...
Lilly Novo Nordisk Battle Intensifies as Obesity Drugs Surge
Eli Lilly's Q1 2026 results slam the lid on the GLP-1 duopoly's early calm, with Lilly’s revenue exploding and Novo N...